{
    "id": 14779,
    "fullName": "CD74 - NRG1",
    "impact": "fusion",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "CD74-NRG1 results from the fusion of CD74 and NRG1, resulting in a ligand for Erbb2 and Erbb3 dimers and leading to Erbb3 activation and downstream Pi3k pathway activation (PMID: 24469108).",
            "references": [
                {
                    "id": 4049,
                    "pubMedId": 24469108,
                    "title": "CD74-NRG1 fusions in lung adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24469108"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 972,
        "geneSymbol": "CD74",
        "terms": [
            "CD74",
            "DHLAG",
            "HLADG",
            "Ia-GAMMA",
            "II",
            "p33"
        ]
    },
    "variant": "CD74 - NRG1",
    "createDate": "12/06/2015",
    "updateDate": "12/06/2015",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 3084,
                "geneSymbol": "NRG1",
                "terms": [
                    "NRG1",
                    "ARIA",
                    "GGF",
                    "GGF2",
                    "HGL",
                    "HRG",
                    "HRG1",
                    "HRGA",
                    "MST131",
                    "MSTP131",
                    "NDF",
                    "NRG1-IT2",
                    "SMDF"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 13746,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, two lung cancer patients harboring CD74-NRG1 did not respond to Gilotrif (afatinib) treatment (PMID: 29610121; NCT01966445).",
            "molecularProfile": {
                "id": 15038,
                "profileName": "CD74 - NRG1"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 11263,
                    "pubMedId": 29610121,
                    "title": "Response to ERBB3-Directed Targeted Therapy in NRG1-Rearranged Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29610121"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7554,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gilotrif (afatinib) inhibited Erbb3 downstream signaling and anchorage-independent growth of transformed cells over expressing CD74 - NRG1 in culture (PMID: 24727320).",
            "molecularProfile": {
                "id": 15038,
                "profileName": "CD74 - NRG1"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6416,
                    "pubMedId": 24727320,
                    "title": "Druggable oncogene fusions in invasive mucinous lung adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24727320"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13745,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, a non-small cell lung carcinoma patient harboring CD74-NRG1 was sensitive to GSK2849330 treatment, demonstrating a partial response that lasted one year and seven months and included tumor shrinkage (PMID: 29610121; NCT01966445).",
            "molecularProfile": {
                "id": 15038,
                "profileName": "CD74 - NRG1"
            },
            "therapy": {
                "id": 2919,
                "therapyName": "GSK2849330",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11263,
                    "pubMedId": 29610121,
                    "title": "Response to ERBB3-Directed Targeted Therapy in NRG1-Rearranged Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29610121"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7552,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tykerb (lapatinib) inhibited Erbb3 downstream signaling and anchorage-independent growth of transformed cells over expressing CD74 - NRG1 in culture (PMID: 24727320).",
            "molecularProfile": {
                "id": 15038,
                "profileName": "CD74 - NRG1"
            },
            "therapy": {
                "id": 787,
                "therapyName": "Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6416,
                    "pubMedId": 24727320,
                    "title": "Druggable oncogene fusions in invasive mucinous lung adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24727320"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 15038,
            "profileName": "CD74 - NRG1",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}